Navigation Links
VIVUS Announces New Qsymia Offer
Date:3/5/2013

us.com/">www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, our limited commercial experience with Qsymia in the U.S.; the timing of initiation and completion of the clinical studies required as part of the approval of Qsymia by the United States Food and Drug Administration, or FDA; the response from the FDA to the data that VIVUS will submit relating to post-approval clinical studies; the impact of the indicated uses and contraindications contained in the Qsymia label and the Risk Evaluation and Mitigation Strategy, or REMS, requirements; the impact of distribution of Qsymia through a certified home delivery pharmacy network; whether or not the FDA approves our amendment to the REMS for Qsymia, which, if approved, would allow dispensing through select certified retail pharmacies to increase access while meeting all requirements of the REMS; that we may be required to provide further analysis of previously submitted clinical trial data; the negative opinion of the European Medicines Agency's, or EMA, Committee for Medicinal Products for Human Use, or CHMP, for the Marketing Authorization Application, or MAA, for Qsymia; our ability to successfully commercialize or establish a marketing partnership for avanafil, which will be marketed in the U.S. under the name STENDRA™; the ability of our partners to obtain and maintain regulatory approvals to manufacture and adequately supply our products to meet demand; our history of losses and v
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sequenom Announces Participation At The Barclays Global Healthcare Conference
2. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
3. Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders
4. SI-BONE, Inc. Announces Spring Society Meeting Attendance
5. Relmada Therapeutics Announces LevoCap ER Development Progress
6. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
7. Evofem Announces Strategic Alliance with WomanCare Global
8. DMH International Announces Agreement with MyDICOM and ChangZhou Wealth Information & Technology Co. Ltd
9. Hill-Rom Announces Second Quarter 2013 Dividend
10. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
11. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Affymax, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... privately held medical device company, announced today that it ... Corporation (Tokyo Stock Exchange TYO: 8001) to sell its ... in Japan . ViewRay,s technology, the ... MRI-guided radiation therapy system that images and treats cancer ...
(Date:1/22/2015)...  Amgen (NASDAQ: AMGN ) today announced that it will ... Tuesday, Jan. 27, 2015, after the close of the U.S. financial ... the investment community at 2 p.m. PT. Participating in the call ... chief executive officer, and other members of Amgen,s senior management team. ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Microbiology Testing/Clinical Microbiology Market by Product, Clinical ... 2019" report to their offering. ... techniques for the detection of infectious diseases. The ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a ... reported its second quarter 2011 financial results for the period ended ... the second quarter. Updates since the beginning of ... Multiple Sclerosis (MS) ...
... Aug. 15, 2011 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTCBB: ... and seller of medicine and drugs in the People,s ... for the quarter ended June 30, 2011. Summary financial ... Quarter Financial Highlights Revenues for ...
Cached Medicine Technology:Adeona Reports Second Quarter 2011 Financial Results 2Adeona Reports Second Quarter 2011 Financial Results 3Adeona Reports Second Quarter 2011 Financial Results 4Adeona Reports Second Quarter 2011 Financial Results 5Adeona Reports Second Quarter 2011 Financial Results 6Adeona Reports Second Quarter 2011 Financial Results 7Adeona Reports Second Quarter 2011 Financial Results 8Adeona Reports Second Quarter 2011 Financial Results 9Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 2Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 3Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 4Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 5Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 6Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 7
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Recently, Weddingshe.com has ... catalog, and has announced its highest annual revenues in the ... on its popular glamorous wedding dresses. , According to the ... important wedding dress promotions for them in 2015. This point ...
(Date:1/22/2015)... Four years since the release of their debut recording Love is ... Avasa & Matthew Love – the duo are pleased to announce ... White Swan Records on February 24, 2015. , THE ROAD offers ... to all of us to walk out of the mire of ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
Breaking Medicine News(10 mins):Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... (CRT) for head and neck cancer, performing targeted swallowing ... swallowing function; however, there were no significant differences in ... nine or 12 months following treatment, according to a ... Otolaryngology Head & Neck Surgery , a JAMA ...
... , MONDAY, April 16 (HealthDay News) -- Tattoos and body ... trend in western societies, but a new study in France ... alcohol than their peers. In the study, researchers ... as they left bars and other drinking establishments. The readings ...
... , MONDAY, April 16 (HealthDay News) -- New long-term research ... in heart arteries. Reporting in the April 16 issue ... study has shown the biodegradable Igaki-Tamai stent, made of a ... foreign material in an artery and reducing the occurrence of ...
... (HealthDay News) -- Media multitasking -- the use of more ... time -- may have some positive effects, a new study ... -- which is especially common in young people and could ... games or social networking -- have received widespread publicity. ...
... 16, 2012) Columbia University Medical Center (CUMC) scientists ... (PI3K) gamma and delta play a key role ... a highly aggressive childhood leukemia that is difficult to ... gamma/delta inhibitor can significantly prolong survival in a mouse ...
... should be possible to significantly improve the response of ... at Cold Spring Harbor Laboratory (CSHL), by introducing agents ... immediate surroundings, called the tumor microenvironment. In research ... , CSHL Assistant Professor Mikala Egeblad and her team ...
Cached Medicine News:Health News:Swallowing exercises linked with short-term improvement among patients with head and neck cancer 2Health News:Tattoos, Piercings Tied to Heavier Drinking in French Study 2Health News:Dissolvable Heart Artery Stents Appear Safe in Study 2Health News:Media Multitasking Might Have Mental Upside 2Health News:Study identifies potential treatment for lethal childhood leukemia 2Health News:Study identifies potential treatment for lethal childhood leukemia 3Health News:Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment 2Health News:Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment 3
Blunt tipped forceps wlth a small grasping platform on each tip. For grasping fine membranes or grasping membranes adherent to the retinal surface....
Blunt tipped forceps with a smooth, pliable silicone coating on the entire interior surface of the tip. For removal of foreign bodies or atraumatic tissue grasping....
Blunt tipped forceps with small, slightly rounded tips angled perpendicular to the shaft. For grasping peripheral membranes....
Blunt tipped forceps with small, slightly pointed grasping platforms on each tip. For general purpose (fine) membrane grasping and grasping membranes adherent to the retlnal surface....
Medicine Products: